New labels are arriving on this shelf faster in 2026 than in any year we have been buying for it, and we are not going to name the unproven ones. A brand with no history cannot be judged by its branding — only by its documents. What follows is a neutral survey of what is actually appearing, and a specific list of what to demand from a company you have never heard of.
We are a distributor and retailer, not a manufacturer. We do not blend or formulate anything; we decide which third-party brands to carry and which to pass on. That gives us a particular view of new entrants: we see the paperwork before the marketing, and the gap between the two is usually the whole story.
What is actually landing in 2026
Four things describe most of the new arrivals.
More categories on one shelf. A store that carried one kind of product two years ago now carries several: kratom-free botanical blends marketed around Uncaria (cat's claw), kava, kanna, functional mushrooms, and combination products that mix two or three of those. Brands that started in one lane are launching lines in the others.
More formats per brand. A single line now commonly ships as pressed tablets, single-serve sachets and liquid shots at once. That multiplies SKUs quickly, and it multiplies the number of distinct batches a brand has to be able to document.
Relabelling and relaunch. The DEA filed two Notices of Intent on 1 July 2026, published in the Federal Register on 6 July. Companies whose existing lines are affected are reformulating, and a reformulated line usually appears under a new name. Some of what looks like a brand-new company is an established operation with new artwork.
White label as the default. Most brands in this industry are labels on someone else's production line. That is normal in supplements generally and not inherently a problem — contract manufacturers can be excellent. It does mean the brand name on the front tells you nothing about who made the contents, and a new name carries no history at all.
We will say plainly that we are in the middle of our own rename, from Cat's Claw to Botanical Blends. A new name is not evidence of anything, good or bad. It is simply a reason to look at the documents rather than the logo.
A new brand is a paperwork question
Taste, packaging design, influencer presence and price tell you nothing about whether a product is what it says it is. With an established brand you can at least look at a record — years of batches, a recall history, whether they answered when something went wrong. A brand launched three months ago has no record, so every question collapses into one: what can they show you, and does it match the unit in your hand?
Four demands cover almost all of it.
1. Batch-level certificates, matched to your unit
A Certificate of Analysis applies to one production lot. "We are third-party tested" as a homepage sentence is not a claim about the product you are buying; a brand that tested one batch in 2024 can say it forever. What you want is a report whose lot number matches the lot printed on your package, whose test date sits close to the manufacture date, and which names an actual laboratory with an accreditation — ISO/IEC 17025 is the standard for testing-laboratory competence — rather than a logo with no address. Our reports are organised by batch on the COA page, and the failure modes are catalogued in our post on COA red flags.
2. A named manufacturer with a real address
US supplement labels carry a name and place of business, but that line can read "Distributed by" and satisfy the requirement without ever identifying who made the product. Ask directly: which facility manufactured this, and where is it. Dietary supplement manufacturing in the US operates under a good manufacturing practice regime with facility registration behind it, so the answer exists — a brand that will not give it is choosing not to.
An address you can look up matters more than it sounds. A mail-drop suite number shared by a dozen companies, or a registered agent's office in a state with no operations, is a different answer to the same question.
3. An analyte list that covers what is actually being scheduled
This is the demand most buyers skip and the one that matters most this year.
Most panels in this market cover the familiar alkaloid set: mitragynine, 7-hydroxymitragynine, speciociliatine, speciogynine, paynantheine, corynantheidine. That is a useful panel. It is not the same panel as the one the 2026 scheduling actions describe.
The first notice, FR Doc 2026-13580, covers 7-hydroxymitragynine above a threshold — 0.050% w/w, or 1.00 milligram per article. The second, FR Doc 2026-13581, covers mitragynine pseudoindoxyl, MGM-15 and MGM-16, with no threshold at all. A certificate reporting non-detect for mitragynine and 7-OH says nothing whatsoever about those three compounds, because the method never looked for them. We wrote up what they are in our explainer on MGM-15 and MGM-16, and both notices are readable at federalregister.gov.
So the question to a new brand is precise: does your laboratory method include mitragynine pseudoindoxyl, MGM-15 and MGM-16, and were certified reference standards used? If the answer is no, then nobody — including that brand, and including us — can honestly say the product is free of them. We hold ourselves to the same line. The certificates supplied for the products we carry report non-detect for 7-hydroxymitragynine, mitragynine, speciociliatine, speciogynine, paynantheine, corynantheidine and mitraphylline, and they do not include mitragynine pseudoindoxyl, MGM-15, MGM-16 or corynoxine B. We therefore do not claim our products are free of those compounds, and you should be suspicious of any brand that does.
4. Packaging that names who made it
The unit itself should carry: a lot code, a date, net contents, the supplement facts or ingredient panel, an identifiable company with a physical address, a contact route, and an age statement. If the lot code lives only on the outer carton, the link between your product and its certificate disappears the moment the box does.
Red flags
- A certificate with no lot number, or a lot number that matches nothing on the package.
- The laboratory name or accreditation removed, cropped, or replaced by a logo.
- One report reused across several products or flavours.
- A test date years old, or earlier than the manufacture date.
- "Lab tested" as a graphic, with no document behind it anywhere on the site.
- A QR code that opens a marketing page instead of a batch record.
- A company that appeared this quarter with forty SKUs already listed.
- Any claim to be "free of all scheduled compounds" or to contain "no Schedule I substances" — no ordinary panel in this market supports that sentence, so it is a claim about marketing, not chemistry.
- Disease claims, or copy that describes a product by comparison to a controlled substance.
- No age gate, no returns policy, no physical address, and no answer to an email.
What 5 August 2026 means for a brand launching now
Both notices take effect on or after 5 August 2026, on the date the scheduling order publishes. The temporary scheduling runs two years and can be extended by one, and it is not subject to judicial review under 21 U.S.C. 811(h)(6). There is no grace period and no sell-through window — stock does not become compliant because it was purchased earlier.
A brand launching in the weeks either side of that date is launching into a rule change, and it is fair to ask what its plan is: what happens to product already in transit, whether its formulations were designed around the notices or before them, and whether it will publish new certificates against the new list. We walked through the mechanics in what changes on August 5. State law adds a second layer on top, and it varies, so the answer where you live may differ from the federal answer.
How we decide what to carry
Our process is deliberately slow, and it is the reason the collection is short rather than long. Before a brand is listed we ask for batch certificates rather than a sample report, we ask who manufactures the product and where, we read the analyte list rather than the summary line, and we require lot codes on the units themselves. If a brand cannot produce those, we do not list it — and we would rather explain a thin catalogue than a claim we cannot support. The longer version is in how we vet brands, and retailers evaluating us on the same terms can start at the wholesale page.
Frequently Asked Questions
Should I avoid a brand just because it is new?
No. New is not the problem; unverifiable is. A six-month-old company that publishes batch-matched certificates, names its manufacturer and answers email is in better shape than a five-year-old company that does none of those things. Judge the documents.
What if a brand says its testing is confidential?
Then it is not testing you can use. Formulation ratios are legitimately proprietary; the identity of the laboratory, the lot number, the analyte list and the results are the entire point of a certificate. A report you are not allowed to see does not function as evidence.
How can I tell whether two brands come from the same manufacturer?
Compare the "manufactured for" or "distributed by" lines, the facility addresses if given, the lot-code format, and the physical packaging — identical blister tooling, identical bottle and cap, identical sachet dimensions. None of that is proof, and shared manufacturing is not a criticism. It is simply useful context when a "new" brand appears.
Are you adding new brands this year?
Only on the terms above. We would rather carry fewer lines we can document than a wide catalogue we cannot, and we will say so plainly when a brand we like has not cleared that bar yet.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Legality depends on the specific formulation and applicable state law — check the rules where you live. Nothing here is legal advice.